Dr Mark Lee

Radiation Oncologist
Become a Patient

Dr Mark Lee delivers comprehensive, personalised treatment to his patients through incorporation of his extensive clinical cancer research knowledge.  He is a highly experienced, confident radiation oncologist who is committed to providing the highest level of care to his patients.


Dr Mark Lee is a senior radiation oncologist consulting at Icon Cancer Centre Revesby.  He has extensive clinical and research experience in the most advanced techniques in radiation therapy including stereotactic radiation therapy for liver, pancreatic cancer and other tumours in the abdomen. Dr Lee completed a Masters of Science at the University of Toronto and undertook fellowship training in stereotactic body radiation therapy for liver cancer at Princess Margaret Hospital in Toronto, Canada. Working for 3 years as a consultant radiation oncologist in the Peter MacCallum Cancer Centre then moving to Sydney to work at Liverpool Hospital. He has been a supervisor of several PhD applicants with research focused on predictive imaging biomarkers and treatments in head and neck and skin cancer. He is currently the chair of the Colorectal Cancer Multi-disciplinary Team Meeting at Liverpool Hospital.

Dr Lee is actively involved in education, research and clinical trials and is an active member in the Australian Gastro-Intestinal Trials Group. His current research interests include use of novel functional imaging with MRI and PET for assessment of tumour response and prognosis for both head and neck and gastrointestinal cancers and has started a stereotactic liver and pancreatic cancer program in Liverpool Hospital. He is actively involved in translational biomarker research with investigators from the Ingham Institute in Liverpool, New South Wales. He is the site primary investigator of multiple study at Liverpool Hospital including international studies for gastric cancer and a novel agents to reduce mucositis during head and neck radiation therapy.

Dr Lee has been involved in education sessions with the International Atomic Energy Agency and implementation of a stereotactic liver radiation therapy research protocol and is currently involved in the quality assurance of an IAEA international trial. He is currently on the accreditation panel for RANZCR registrar training and was previously an elected member to the RANZCR education committee.

Dr Lee is a leading radiation oncologist specialising in the use of TomoTherapy, Intensity Modulated Radiation Therapy [IMRT], Image Guided Radiation Therapy [IGRT] and stereotactic radiation therapy. His clinical experience covers a broad range of solid tumour malignancies, with special clinical interests in head and neck, gastrointestinal and skin cancers, and re-irradiation and palliative radiation therapy treatments.

Affiliations & Memberships

  • Royal Australian and New Zealand College of Radiologists (RANZCR)
  • American Society of Radiation Oncology
  • Australian Gastro-Intestinal Trials Group (AGITG)
  • Trans Tasman Radiation Oncology Group (TROG)

Special Interests

Dr Mark Lee accepts referrals for all cancer types, with a special clinical interest in:
  • Gastrointestinal cancer
  • Head and neck cancer
  • Palliative care
  • Skin cancer
  • Stereotactic radiation therapy

Icon Locations

Revesby View centre


  • Comparison of four dimensional computed tomography and magnetic resonance imaging in abdominal radiotherapy planning. Andrew Oar, Gary Liney, Robba Rai, Shrikant Deshpande, Li Pan, Meredith Johnston, Michael Jameson, Shivani Kumar, Mark Lee. Physics and Imaging in Rad Oncology, 2018; 7: 70-75.

  • An assessment of set-up position for MRI scanning for the purposes of rectal cancer radiotherapy treatment planning. Ewa Juresic, Gary Liney, Robba Rai, Joseph Descalar, Mark Lee, Karen Wong, Daniel Moses, Jacqueline Veera, Lois Holloway. Journal of Medical Radiation Sciences, 2018; 65(1): 22-30.

  • Differences in LC3B Expression and Prognostic implications in Oropharyngeal and Oral Cavity Squamous Cell Carcinoma Patients. Kenneth Lai, Slade Matthews, James S. Wilmott, Murray C. Killingsworth, Jim L. Yong, Nicole J. Caixeiro, James Wykes, Allan Samakeh, Dion Forstner, Mark Lee, John McGuinness, Navin Niles, Angela Hong, Ardalan Ebrahimi, Cheok Soon Lee. BMC Cancer, 2018; 18(1): 624.


  • Nodal parameters of FDG PET/CT performed during radiotherapy for locally advanced mucosal primary head and neck squamous cell carcinoma can predict treatment outcomes: SUVmean and response rate are useful imaging biomarkers. Peter Lin, Myo Min, Mark Bryan Lee, Lois C. Holloway, Dion F. Forstner, Victoria Bray, Allan Fowler. European Journal of Nuclear Medicine and Molecular Imaging, 2017; 44(5) 801-811. 


  • Clinical significance of treatment delivery errors for helical TomoTherapy Nasopharyngeal plans – A dosimetric simulation study. Shirkant Deshpande, Mark Geurts, Philip J. Vial, Peter Metcalfe, Mark Lee, Lois C. Holloway. Physics Med, 2017 Jan;33:159-169.